2018 ACVIM Forum Research Abstract Program: Seattle, Washington, June 14 - 15, 2018

In this study, an increase in serum SDMA was observed in both Propofol-and Alphaxalone-treated dogs, whereas the levels of sCr and BUN only increased in Propofol-treated dogs. Taken together, these data suggest that serum SDMA concentration is likely to be a sensitive biomarker for kidney dysfunction. The present data shows that serum SDMA has a strong relationship with several parameters used in the evaluation of renal function, such as serum creatinine, serum phosphorus, serum BUN, hematocrit, UP/C, urinary density and reticulocytes. Serum SDMA had a weak relationship with BP. Serum SDMA increased prior to image alteration on kidney ultrasonography in 13.3% (3/30) of the dogs. Serum SDMA also increased in 15% (9/60) of dogs before values of serum creatinine were above 1.4mg / dl. The differences found in IRIS staging considering serum SDMA were: of the dogs in IRIS stage 2, 33.3% (2/6) had serum SDMA above 25μg / dl, so these dogs were reclassified from IRIS stage 2 to IRIS stage 3. Dogs in IRIS stage 3, 16.6% (1/6) had serum SDMA above 45μg / dl so this dog was reclassified from IRIS stage 3 to IRIS stage 4. So we conclude that serum SDMA is an important tool for the evaluation of renal function and should be used routinely in the evaluation of dogs infected with L. infantum. Samples were thawed in batches and analyzed once using Cata-lystSDMA, on a Catalyst One® Chemistry Analyzer, and once using LC-MS (RefMethod). The study was completed over several days, however, for each sample, all testing was completed within four hours.